Publications by authors named "Martha MacLean"

Claim this Profile
P
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Miguel Quintela-Fandino, Christophe Le Tourneau, Ignacio Duran, Eric X Chen, Lisa Wang, Martha MacLean

Mol Cancer Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
Eric Chen, Derek Jonker, Isabelle Gauthier, Martha MacLean, Julie Wells

Clin Cancer Res· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Sébastien J Hotte, Hal W Hirte, Eric X Chen, Lillian L Siu, Lyly H Le, Martha MacLean

Clin Cancer Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Lillian L Siu, Roberto Pili, Ignacio Duran, Wells A Messersmith, Eric X Chen, Martha MacLean

J Clin Oncol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Ignacio Duran, Sebastien J Hotté, Holger Hirte, Eric X Chen, Martha MacLean

Clin Cancer Res· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial.
Elizabeth L Strevel, Colin Newman, Gregory R Pond, Martha MacLean, Lillian L Siu

Support Care Cancer· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Tara Baetz, Elizabeth Eisenhauer, Lillian Siu, Martha MacLean, Karen Doppler

Invest New Drugs· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
Anthony Brade, James Brierley, Amit Oza, Steven Gallinger, Bernard Cummings, Martha Maclean

Int J Radiat Oncol Biol Phys· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital.
Jeremy Ho, Gregory R Pond, Colin Newman, Martha Maclean, Eric X Chen

BMC Cancer· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.
Eric X Chen, Gerald Batist, Lillian L Siu, Naeema Bangash, Martha Maclean

Invest New Drugs· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
Lyly H Lê, Malcolm J Moore, Lillian L Siu, Amit M Oza, Martha MacLean

Cancer Chemother Pharmacol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.
Alison J Davis, Karen A Gelmon, Lillian L Siu, Malcolm J Moore, Carolyn D Britten, Martha MacLean

Invest New Drugs· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Karl Bélanger, Malcolm Moore, Sharyn D Baker, Jeanne Dionne, Martha Maclean

J Clin Oncol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis